<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>血液肿瘤资讯 | wechat-feeds</title><link>http://MzU4NjkzMDg4Mw.favicon.privacyhide.com/favicon.ico</link><description>良医汇【肿瘤资讯】旗下公众号，专注于血液肿瘤的前沿学术进展。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 11 Apr 2021 19:19:57 +0800</pubDate><image><url>http://MzU4NjkzMDg4Mw.favicon.privacyhide.com/favicon.ico</url><title>血液肿瘤资讯 | wechat-feeds</title><link>http://MzU4NjkzMDg4Mw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【672】指南第一线｜高级别B细胞淋巴瘤（HGBL）诊疗——NCCN指南更新点</title><link>https://mp.weixin.qq.com/s/kVcwa-BZ_dniDvMLunch3g</link><description></description><content:encoded><![CDATA[【672】指南第一线｜高级别B细胞淋巴瘤（HGBL）诊疗——NCCN指南更新点]]></content:encoded><pubDate>Sun, 11 Apr 2021 16:43:32 +0800</pubDate></item><item><title>【670】GENUINE 3期研究最新结果：伊布替尼联合新型CD20抗体可提高高危R/R CLL患者有效率</title><link>https://mp.weixin.qq.com/s/sdhcqOv-YcUC4OgsqyEcsA</link><description></description><content:encoded><![CDATA[【670】GENUINE 3期研究最新结果：伊布替尼联合新型CD20抗体可提高高危R/R CLL患者有效率]]></content:encoded><pubDate>Sat, 10 Apr 2021 17:59:33 +0800</pubDate></item><item><title>慢性粒细胞白血病疾病转化及停药的研究进展</title><link>https://mp.weixin.qq.com/s/YGfZDaxS2x-wCPG_RsfVqA</link><description></description><content:encoded><![CDATA[慢性粒细胞白血病疾病转化及停药的研究进展]]></content:encoded><pubDate>Sat, 10 Apr 2021 17:59:33 +0800</pubDate></item><item><title>【669】如何规范化应用生物类似药？最新专家共识来了！</title><link>https://mp.weixin.qq.com/s/ZN1kvIPIQn3NXsyEaeXXVQ</link><description></description><content:encoded><![CDATA[【669】如何规范化应用生物类似药？最新专家共识来了！]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:28:32 +0800</pubDate></item><item><title>【柳叶刀·血液】Elotuzumab联合RVd的四药方案能否为不适合ASCT的高危NDMM患者“增效添彩”？</title><link>https://mp.weixin.qq.com/s/Cvi0i8jbl33soITANevbyg</link><description></description><content:encoded><![CDATA[【柳叶刀·血液】Elotuzumab联合RVd的四药方案能否为不适合ASCT的高危NDMM患者“增效添彩”？]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:28:32 +0800</pubDate></item><item><title>【668】【JCO】MRD阴性率更高，PFS更长，达雷妥尤单抗方案使RRMM获益显著</title><link>https://mp.weixin.qq.com/s/xmUUjTU-7tBRpoGmjW4pvQ</link><description></description><content:encoded><![CDATA[【668】【JCO】MRD阴性率更高，PFS更长，达雷妥尤单抗方案使RRMM获益显著]]></content:encoded><pubDate>Thu, 08 Apr 2021 17:55:02 +0800</pubDate></item><item><title>口服阿扎胞苷能否使低危MDS患者获益？</title><link>https://mp.weixin.qq.com/s/s-r6C8hsJMr9-JtR8gvzeg</link><description></description><content:encoded><![CDATA[口服阿扎胞苷能否使低危MDS患者获益？]]></content:encoded><pubDate>Thu, 08 Apr 2021 17:55:02 +0800</pubDate></item><item><title>【667】CD30靶向药物推动PTCL与CTCL治疗模式的变革——靶向CD30的ADC维布妥昔单抗治疗PTCL与CTCL</title><link>https://mp.weixin.qq.com/s/5fZU-T3dj08XDZLEUVXVbw</link><description></description><content:encoded><![CDATA[【667】CD30靶向药物推动PTCL与CTCL治疗模式的变革——靶向CD30的ADC维布妥昔单抗治疗PTCL与CTCL]]></content:encoded><pubDate>Wed, 07 Apr 2021 17:22:38 +0800</pubDate></item><item><title>【中国好声音】侯明教授团队探索如何优化ITP一线治疗方案，最新结果发表在Lancet Haematology</title><link>https://mp.weixin.qq.com/s/gcEXJYo4BY2M882SZppczg</link><description></description><content:encoded><![CDATA[【中国好声音】侯明教授团队探索如何优化ITP一线治疗方案，最新结果发表在Lancet Haematology]]></content:encoded><pubDate>Wed, 07 Apr 2021 17:22:38 +0800</pubDate></item><item><title>【666】指南第一线｜伯基特淋巴瘤（BL）NCCN诊疗指南更新要点速览</title><link>https://mp.weixin.qq.com/s/UD4C_WE4vlTsH4F25J7Q0w</link><description></description><content:encoded><![CDATA[【666】指南第一线｜伯基特淋巴瘤（BL）NCCN诊疗指南更新要点速览]]></content:encoded><pubDate>Tue, 06 Apr 2021 17:35:13 +0800</pubDate></item><item><title>弥漫大B细胞淋巴瘤分子病理分型研究进展</title><link>https://mp.weixin.qq.com/s/Lj5aQETYv4kdWWyKdv9ihg</link><description></description><content:encoded><![CDATA[弥漫大B细胞淋巴瘤分子病理分型研究进展]]></content:encoded><pubDate>Tue, 06 Apr 2021 17:35:13 +0800</pubDate></item><item><title>【665】一文速览|血液学核心期刊文献精选（3月）</title><link>https://mp.weixin.qq.com/s/Q4NZ1n33c_vdSTF9sH3b-A</link><description></description><content:encoded><![CDATA[【665】一文速览|血液学核心期刊文献精选（3月）]]></content:encoded><pubDate>Mon, 05 Apr 2021 15:52:21 +0800</pubDate></item><item><title>【664】必看｜美国肿瘤免疫治疗学会(SITC)免疫治疗淋巴瘤临床实践指南（下篇）</title><link>https://mp.weixin.qq.com/s/ce2hmZ8leg141TyjTvo_PQ</link><description></description><content:encoded><![CDATA[【664】必看｜美国肿瘤免疫治疗学会(SITC)免疫治疗淋巴瘤临床实践指南（下篇）]]></content:encoded><pubDate>Sat, 03 Apr 2021 22:42:12 +0800</pubDate></item><item><title>【663】推陈出“欣”·经验之谈｜柳暗花明——一例复发难治FL患者的诊治经过</title><link>https://mp.weixin.qq.com/s/VQ7_DC50ggeB0ssgCtStdA</link><description></description><content:encoded><![CDATA[【663】推陈出“欣”·经验之谈｜柳暗花明——一例复发难治FL患者的诊治经过]]></content:encoded><pubDate>Sat, 03 Apr 2021 17:28:10 +0800</pubDate></item><item><title>【662】指南第一线｜边缘区淋巴瘤（MZL）诊疗NCCN指南更新点</title><link>https://mp.weixin.qq.com/s/Y7_J_jonOtz7NTq9am50Hg</link><description></description><content:encoded><![CDATA[【662】指南第一线｜边缘区淋巴瘤（MZL）诊疗NCCN指南更新点]]></content:encoded><pubDate>Fri, 02 Apr 2021 17:09:55 +0800</pubDate></item><item><title>【中华淋巴瘤大会】张智慧教授：免疫化疗是高级别B细胞淋巴瘤的公认方案，新型药物或可带动治疗格局发展</title><link>https://mp.weixin.qq.com/s/4wE8RczkblkIIRaSvUWhqg</link><description></description><content:encoded><![CDATA[【中华淋巴瘤大会】张智慧教授：免疫化疗是高级别B细胞淋巴瘤的公认方案，新型药物或可带动治疗格局发展]]></content:encoded><pubDate>Fri, 02 Apr 2021 17:09:55 +0800</pubDate></item><item><title>新鲜出炉丨2021CSCO指南会最新日程</title><link>https://mp.weixin.qq.com/s/KOVpLQfnpHWi8D9iujAcDQ</link><description></description><content:encoded><![CDATA[新鲜出炉丨2021CSCO指南会最新日程]]></content:encoded><pubDate>Fri, 02 Apr 2021 17:09:55 +0800</pubDate></item></channel></rss>